Sanofi Announces Settlement Agreement for Zantac Lawsuits in the United States

Thursday 04 April 2024 - 13:00

Sanofi, a leading pharmaceutical company, has announced an agreement in principle to settle approximately 4,000 lawsuits in the United States related to the now-discontinued heartburn medication Zantac. The lawsuits allege a connection between Zantac and cancer, prompting legal action against Sanofi and other defendants. While the financial terms of the settlement were not disclosed, Sanofi clarified that the agreement is subject to finalization.

The settlement aims to resolve the majority of lawsuits against Sanofi in U.S. state courts, excluding cases in Delaware, where a significant portion of the litigation is pending. Despite reaching this agreement, Sanofi emphasized that it does not admit any liability and is settling to avoid the ongoing costs and disruptions associated with litigation.

Throughout the legal proceedings, Sanofi has vigorously defended itself against the allegations surrounding Zantac. The company reiterated its commitment to this stance in its recent statement regarding the settlement. However, Sanofi continues to face approximately 20,000 lawsuits related to Zantac in Delaware state court, awaiting further legal proceedings.

The fate of these lawsuits hinges on a crucial decision from a judge in Delaware Superior Court, who is evaluating the scientific evidence supporting plaintiffs' claims of Zantac's cancer-causing potential. This ruling will have significant implications for both plaintiffs and defendants involved in the litigation against Sanofi and other pharmaceutical companies, including GSK, Pfizer, and Boehringer Ingelheim.

In a notable development, Sanofi and other drugmakers achieved a legal victory in 2022 when a judge dismissed around 50,000 lawsuits consolidated in federal court in Florida. The judge determined that the evidence presented by plaintiffs' expert witnesses lacked sufficient scientific support. Despite this dismissal, plaintiffs are appealing the ruling, underscoring the complex and ongoing nature of the legal battles surrounding Zantac.

The controversy surrounding Zantac dates back to 2019 when concerns emerged about the presence of the carcinogenic chemical NDMA in the medication. Subsequent investigations revealed that Zantac's active ingredient, ranitidine, could degrade into NDMA under certain conditions. This revelation led to widespread halts in Zantac sales and a surge in lawsuits from individuals alleging cancer development due to Zantac usage.

With the FDA's directive to remove Zantac from the market in 2020, Sanofi has transitioned to offering Zantac360, a reformulated heartburn medication containing famotidine as its active ingredient. As litigation against Sanofi and other defendants continues, the outcome of ongoing legal proceedings will shape the future landscape of Zantac-related claims and pharmaceutical regulations.